<DOC>
	<DOC>NCT01489059</DOC>
	<brief_summary>The purpose of this study is to determine whether the combination of interleukin-21 (IL-21) and Ipilimumab in subjects with melanoma is safe, and provide preliminary information on the clinical benefits of the combination compared with Ipilimumab alone</brief_summary>
	<brief_title>Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma</brief_title>
	<detailed_description>Allocation: Part 1 Dose Escalation Phase: Non-randomized; Part 2 Cohort Expansion Phase: Randomized</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Unresectable Stage III or Stage IV melanoma Part 1 Dose Escalation: Prior melanoma treatment allowed except for the following: ipilimumab, BMS982470 (rIL21), antiProgrammed Death1 (antiPD1), antiprogrammed deathligand 1 (antiPDL1), antiPDL2 or antiCD137 Part 2 Cohort expansion: Prior treatment for melanoma is not allowed, except for adjuvant therapy with interferon alpha or melanoma vaccines which are permitted Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) Normal liver function tests Part 1 Dose escalation: subjects with ≤ 2 brain metastases of stable size, ≥ 4 weeks postradiation treatment, and off steroids are allowed Part 2 Cohort expansion: subjects with known or suspected brain metastases and uveal melanoma are excluded Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>